Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy

• Published in: Biomarker research Vol. 12; no. 1; p. 41
• Main Authors: Shan, Yukai, Xie, Tianao, Sun, Yuchao, Lu, Ziyi, Topatana, Win, Juengpanich, Sarun, Chen, Tianen, Han, Yina, Cao, Jiasheng, Hu, Jiahao, Li, Shijie, Cai, Xiujun, Chen, Mingyu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.04.2024; BioMed Central; BMC
• Subjects: Antigens; Autoimmune diseases; Body fat; Cancer; Chemokines; Cholesterol; Cytokines; Development and progression; Effector cells; Energy; Fatty acids; Genotype & phenotype; Glucose; Immune checkpoint; Immune system; Immunomodulation; Immunoregulation; Immunosuppression; Immunotherapy; Inflammation; Kinases; Lipid metabolism; Lipids; Lymphocytes; Lymphocytes T; Medical prognosis; Metabolic competition; Metabolic regulatory switches; Metabolism; Oxidation; Phosphorylation; Physiological aspects; Proteins; Review; T cells; Transcription factors; Tregs; Tumor therapies; Tumor-infiltrating lymphocytes; Tumors; Type 2 diabetes; Metabolic competition; Immunosuppression; Metabolic regulatory switches; Lipid metabolism; Tregs; Tumor therapies
• ISSN: 2050-7771; 2050-7771
• DOI: 10.1186/s40364-024-00588-8

Regulatory T cells (Tregs) are essential to the negative regulation of the immune system, as they avoid excessive inflammation and mediate tumor development. The abundance of Tregs in tumor tissues suggests that Tregs may be eliminated or functionally inhibited to stimulate antitumor immunity. However, immunotherapy targeting Tregs has been severely hampered by autoimmune diseases due to the systemic elimination of Tregs. Recently, emerging studies have shown that metabolic regulation can specifically target tumor-infiltrating immune cells, and lipid accumulation in TME is associated with immunosuppression. Nevertheless, how Tregs actively regulate metabolic reprogramming to outcompete effector T cells (Teffs), and how lipid metabolic reprogramming contributes to the immunomodulatory capacity of Tregs have not been fully discussed. This review will discuss the physiological processes by which lipid accumulation confers a metabolic advantage to tumor-infiltrating Tregs (TI-Tregs) and amplifies their immunosuppressive functions. Furthermore, we will provide a summary of the driving effects of various metabolic regulators on the metabolic reprogramming of Tregs. Finally, we propose that targeting the lipid metabolism of TI-Tregs could be efficacious either alone or in conjunction with immune checkpoint therapy.